Details for Patent: 9,358,235

Which drugs does patent 9,358,235 protect, and when does it expire?

Patent 9,358,235 protects TURALIO and is included in one NDA.

This patent has twenty-two patent family members in fifteen countries.

Summary for Patent: 9,358,235

Title:	Kinase modulation, and indications therefor
Abstract:	The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.
Inventor(s):	Bollag; Gideon (Hercules, CA), Hirth; Klaus-Peter (San Francisco, CA), Ibrahim; Prabha N. (Mountain View, CA), Lin; Paul (Oakland, CA), West; Brian (San Francisco, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	13/802,106
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,358,235

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	No						TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No						TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY

International Family Members for US Patent 9,358,235

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013235298
Australia	2017254821
Brazil	112014023162
Canada	2867918